Inhibikase Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2020 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Inhibikase Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2020 to Q4 2023.
  • Inhibikase Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $18.8M, a 51.5% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $18.8M +$6.37M +51.5% Dec 31, 2023 10-K 2024-03-27
Q4 2022 $12.4M +$4.91M +65.7% Dec 31, 2022 10-K 2024-03-27
Q4 2021 $7.48M +$3.81M +104% Dec 31, 2021 10-K 2023-03-31
Q4 2020 $3.66M Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.